[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nexalin Technology Inc (NXL)

Nexalin Technology Inc (NXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,774
  • Shares Outstanding, K 20,582
  • Annual Sales, $ 300 K
  • Annual Income, $ -8,220 K
  • EBIT $ -9 M
  • EBITDA $ -8 M
  • 60-Month Beta 3.56
  • Price/Sales 27.19
  • Price/Cash Flow N/A
  • Price/Book 2.85
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.47
  • Most Recent Earnings $-0.11 on 05/08/26
  • Next Earnings Date 08/05/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Business Services
  • INDUSTRY GROUPING Technology Services

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3050 +23.84%
on 05/20/26
0.5023 -24.81%
on 05/22/26
-0.0922 (-19.62%)
since 04/22/26
3-Month
0.3050 +23.84%
on 05/20/26
0.6499 -41.88%
on 02/24/26
-0.1204 (-24.17%)
since 02/20/26
52-Week
0.3050 +23.84%
on 05/20/26
2.0000 -81.11%
on 10/08/25
-0.8323 (-68.79%)
since 05/22/25

Most Recent Stories

More News
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic...

NXL : 0.3777 (-5.34%)
NXLIW : 0.0138 (-9.21%)
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

HOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...

NXL : 0.3777 (-5.34%)
NXLIW : 0.0138 (-9.21%)
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

Publication reports statistically significant improvement in sleep quality following treatment with Nexalin’s 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group ...

NXL : 0.3777 (-5.34%)
NXLIW : 0.0138 (-9.21%)
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

HOUSTON, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...

NXL : 0.3777 (-5.34%)
NXLIW : 0.0138 (-9.21%)
RedChip's Biotech Investor Conference Replays Now Available

ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

NXL : 0.3777 (-5.34%)
BIVI : 1.5200 (+2.70%)
SXTP : 1.4800 (-0.67%)
BFRG : 0.6540 (-1.65%)
LTRN : 3.50 (+5.42%)
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China

HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...

NXL : 0.3777 (-5.34%)
NXLIW : 0.0138 (-9.21%)
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21

ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW). The exclusive...

NXL : 0.3777 (-5.34%)
NXLIW : 0.0138 (-9.21%)
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin’s differentiated, non-invasive...

NXL : 0.3777 (-5.34%)
NXLIW : 0.0138 (-9.21%)
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference

ORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...

NXL : 0.3777 (-5.34%)
BIVI : 1.5200 (+2.70%)
SXTP : 1.4800 (-0.67%)
BFRG : 0.6540 (-1.65%)
LTRN : 3.50 (+5.42%)
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment Builds on Prior Peer-Reviewed...

NXL : 0.3777 (-5.34%)
NXLIW : 0.0138 (-9.21%)

Business Summary

Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas.

See More

Key Turning Points

3rd Resistance Point 0.6196
2nd Resistance Point 0.5610
1st Resistance Point 0.4693
Last Price 0.3777
1st Support Level 0.3190
2nd Support Level 0.2604
3rd Support Level 0.1687

See More

52-Week High 2.0000
Fibonacci 61.8% 1.3525
Fibonacci 50% 1.1525
Fibonacci 38.2% 0.9525
Last Price 0.3777
52-Week Low 0.3050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.